A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by

Trial Details

NCT ID

NCT06562543

Phase

PHASE4

Sponsor

Takeda

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Fruquintinib

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249
Birmingham, Alabama, United States|33.52066,-86.80249
Chandler, Arizona, United States|33.30616,-111.84125
Tucson, Arizona, United States|32.22174,-110.92648
La Jolla, California, United States|32.84727,-117.2742

Key Eligibility Criteria

Provide written (or electronic) informed consent.
Male or female aged more than or equal to (≥)18 years.
Presence of histologically and/or cytologically documented metastatic colorectal adenocarcinoma. Rat sarcoma virus (RAS) status for each participan…
Have been previously treated with standard approved therapies:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →